MedTrace Logo

Alpha Lipoic Acid as an Adjuvant Treatment in Acute Phosphide Poisoning

NCT02760823 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2016-05-10

No results posted yet for this study

Summary

The aim of this study is to evaluate efficacy and safety of Alpha Lipoic Acid(ALA) as an adjuvant in the management of patients with acute phosphide poisoning.

Conditions

  • Toxicity

Interventions

DRUG

Alpha Lipoic Acid (Thioctacid)

600 mg/12 hours, IV (in the vein)

DRUG

Placebo (for Alpha Lipoic Acid)

Normal saline in syringe simulating Alpha Lipoic Acid 600mg

Sponsors & Collaborators

  • Tanta University

    collaborator OTHER

  • Heba Allah Ali Abd El-Halim Mabrouk

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2018-01-31
Completion
2018-01-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02760823 on ClinicalTrials.gov